comparemela.com

Page 2 - Eluminex Biosciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eluminex Biosciences Closes $40+ Million Series B Financing to Continue the Development of Innovative Ophthalmic Assets and Recombinant Human Collagen Technology

/PRNewswire/ Eluminex Biosciences (Suzhou) Limited (Eluminex) officially announced today the closing of a Series B financing of over $40 million (USD)..

United statesSouth san franciscoJinzhong zhangEluminex biosciences suzhouEluminex biosciences suzhou limitedOriza holdingsGuangzhou yuexiu industrial investment fund managementEluminex biosciencesCenova capitalBioventures capitalSuzhou industrial parkLilly asia venturesHillhouse capital

Eluminex Biosciences Announces Completion of Initial Enrollment in Part A of the CLARITY Study Evaluating a Human Recombinant Collagen-derived (rhCIII) Biosynthetic Cornea (EB-301)

/PRNewswire/ Eluminex Biosciences today announced the completion of clinical enrollment in Part A (N=5) of a two-part pivotal study (CLARITY) evaluating a.

United statesSan diegoEluminex biosciencesMingchang zhangCharles sembaChina jiangsu medical product agencyAmerican society of cataractCorneal surgery at wuhan union hospitalInitial partAmerican societyRefractive surgery annualJiangsu medical product agencyGreater chinaRefractive surgeryProfessor mingchang zhangCorneal surgery

Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings

Purchase of Assets and Related Global Commercialization Rights for Oral 9-cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness. Clinical Stage Asset.

University of washingtonUnited statesSan francisco bayDavid sapersteinEluminex biosciencesCharles sembaMarco northlandRetinagenix holdingsEluminex biosciences ltd suzhouZuretinol retinal rare pediatric disease programDrug administrationProgram has receivedPrnewswire eluminex biosciences suzhou limitedEuropean unionEuropean medicine agencyRelated global commercialization rights

Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings

Purchase of Assets and Related Global Commercialization Rights for Oral 9-cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness. Clinical .

University of washingtonUnited statesSan francisco bayDavid sapersteinEluminex biosciencesCharles sembaMarco northlandRetinagenix holdingsZuretinol retinal rare pediatric disease programDrug administrationProgram has receivedPrnewswire eluminex biosciences suzhou limitedEuropean unionEuropean medicine agencyRelated global commercialization rightsRare forms

Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings

Purchase of Assets and Related Global Commercialization Rights for Oral 9-cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness. Clinical Stage Asset.

University of washingtonUnited statesSan francisco bayDavid sapersteinEluminex biosciencesCharles sembaMarco northlandRetinagenix holdingsEluminex biosciences ltd suzhouZuretinol retinal rare pediatric disease programDrug administrationProgram has receivedPrnewswire eluminex biosciences suzhou limitedEuropean unionEuropean medicine agencyRelated global commercialization rights

vimarsana © 2020. All Rights Reserved.